DE602004005033D1 - Benzamidinhibitoren des p2x7-rezeptors - Google Patents

Benzamidinhibitoren des p2x7-rezeptors

Info

Publication number
DE602004005033D1
DE602004005033D1 DE602004005033T DE602004005033T DE602004005033D1 DE 602004005033 D1 DE602004005033 D1 DE 602004005033D1 DE 602004005033 T DE602004005033 T DE 602004005033T DE 602004005033 T DE602004005033 T DE 602004005033T DE 602004005033 D1 DE602004005033 D1 DE 602004005033D1
Authority
DE
Germany
Prior art keywords
receptor
benzamidinhibitors
disorders
copd
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004005033T
Other languages
English (en)
Other versions
DE602004005033T2 (de
Inventor
Mark Anthony Dombroski
Allen Jacob Duplantier
Chakrapani Subramanyam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of DE602004005033D1 publication Critical patent/DE602004005033D1/de
Application granted granted Critical
Publication of DE602004005033T2 publication Critical patent/DE602004005033T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE602004005033T 2003-05-12 2004-05-10 Benzamidinhibitoren des p2x7-rezeptors Expired - Lifetime DE602004005033T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47000103P 2003-05-12 2003-05-12
US470001P 2003-05-12
PCT/IB2004/001525 WO2004099146A1 (en) 2003-05-12 2004-05-10 Benzamide inhibitors of the p2x7 receptor

Publications (2)

Publication Number Publication Date
DE602004005033D1 true DE602004005033D1 (de) 2007-04-12
DE602004005033T2 DE602004005033T2 (de) 2007-08-09

Family

ID=33435257

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004005033T Expired - Lifetime DE602004005033T2 (de) 2003-05-12 2004-05-10 Benzamidinhibitoren des p2x7-rezeptors

Country Status (10)

Country Link
US (2) US7186742B2 (de)
EP (1) EP1626962B1 (de)
JP (1) JP4731468B2 (de)
AT (1) ATE355273T1 (de)
BR (1) BRPI0410349A (de)
CA (1) CA2525437C (de)
DE (1) DE602004005033T2 (de)
ES (2) ES2396565T3 (de)
MX (1) MXPA05012086A (de)
WO (1) WO2004099146A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8557501A1 (es) * 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
US7071223B1 (en) * 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) * 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
JP4731468B2 (ja) 2003-05-12 2011-07-27 ファイザー・プロダクツ・インク Ｐ２ｘ７受容体のベンズアミド阻害剤
AU2005258911A1 (en) * 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
EP1763353A1 (de) * 2004-06-29 2007-03-21 Warner-Lambert Company LLC KOMBINATIONSTHERAPIEN MIT BENZAMID-HEMMERN DES P2X<SB>7</SB> REZEPTORS
JP2008514691A (ja) * 2004-09-29 2008-05-08 ケマジス リミティド 薬学的に純粋な非晶質塩酸ドネペジルを製造するための精製されたマレイン酸ドネペジルの使用
JP2008528580A (ja) * 2005-01-27 2008-07-31 アストラゼネカ・アクチエボラーグ Ｐ２ｘ７受容体の阻害剤である新規二環式芳香族化合物
CA2628260A1 (en) * 2005-11-09 2007-05-18 Abbott Laboratories 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof
WO2008055840A1 (en) 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Thiazole and oxazole-substituted arylamides
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
CN101686680B (zh) * 2007-03-09 2015-12-09 伊沃泰克美国股份有限公司 作为p2x7调节剂的双环杂芳基化合物及其用途
EP2139879B1 (de) * 2007-03-22 2012-07-11 AstraZeneca AB Chinolinderivate zur behandlung entzündlicher krankheiten
DK2178865T3 (en) 2007-07-19 2015-10-19 Lundbeck H As 5-membered heterocyclic amides and related compounds
EP2203429A1 (de) 2007-10-31 2010-07-07 Nissan Chemical Industries, Ltd. Pyridazinonderivate und ihre verwendung als p2x7-rezeptorhemmer
ES2417182T3 (es) 2007-12-17 2013-08-06 F. Hoffmann-La Roche Ag Nuevas arilamidas sustituidas con pirazol
CA2707422C (en) * 2007-12-17 2016-06-07 F. Hoffmann-La Roche Ag Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists
BRPI0820838B8 (pt) * 2007-12-17 2021-05-25 Hoffmann La Roche derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3
CN101903355B (zh) * 2007-12-17 2014-05-14 霍夫曼-拉罗奇有限公司 咪唑取代的芳基酰胺
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
SG172190A1 (en) * 2008-12-16 2011-07-28 Hoffmann La Roche Thiadiazole-substituted arylamides
CN102395562A (zh) 2009-04-14 2012-03-28 阿费克蒂斯制药股份公司 新的p2x7r拮抗剂及其用途
CN102803245B (zh) 2009-06-22 2015-02-11 弗·哈夫曼-拉罗切有限公司 作为p2x3和/或p2x2/3拮抗剂的吲哚、吲唑和苯并咪唑芳基酰胺类
SG177308A1 (en) 2009-06-22 2012-02-28 Hoffmann La Roche Novel biphenyl and phenyl-pyridine amides
WO2010149541A1 (en) 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel oxazolone and pyrrolidinone-substituted arylamides
US20130195919A1 (en) 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
EP2386541A1 (de) 2010-05-14 2011-11-16 Affectis Pharmaceuticals AG Neue Verfahren zur Herstellung von P2X7R-Antagonisten
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US20140073651A1 (en) * 2011-02-22 2014-03-13 Actelion Pharmaceuticals Ltd. Benzamide derivatives as p2x7 receptor antagonists
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
BR112014001454A2 (pt) 2011-07-22 2017-06-27 Actelion Pharmaceuticals Ltd derivados de amidas heterocíclicas como antagonistas do receptor de p2x7
CN102993096A (zh) * 2011-09-13 2013-03-27 宁波大学 一种n-吡唑酰胺衍生物及其制备方法
JP6111268B2 (ja) 2012-01-20 2017-04-05 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
TW201427947A (zh) 2012-10-12 2014-07-16 Lundbeck & Co As H 環狀胺
TWI598325B (zh) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 苯甲醯胺類
EP2931717B1 (de) 2012-12-12 2016-12-07 Actelion Pharmaceuticals Ltd. Indolcarboxamidderivate als p2x7-rezeptorantagonisten
US9556117B2 (en) 2012-12-18 2017-01-31 Actelion Pharmaceuticals Ltd. Indole carboxamide derivatives as P2X7 receptor antagonists
EP2956457B1 (de) 2013-01-22 2016-11-23 Actelion Pharmaceuticals Ltd Heterocyclische amidderivate als p2x7-rezeptorantagonisten
EP2956135B1 (de) 2013-01-22 2016-11-16 Actelion Pharmaceuticals Ltd. Heterocyclische amidderivate als p2x7-rezeptorantagonisten
WO2014151953A1 (en) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
EP2905282A1 (de) 2014-02-05 2015-08-12 AXXAM S.p.A. Substituierte Thiazole oder Oxazole als P2X7-Rezeptorantagonisten
PL3287443T3 (pl) 2015-04-24 2022-02-21 Shionogi & Co., Ltd 6-członowa pochodna heterocykliczna i kompozycja farmaceutyczna ją zawierająca
JP6943857B2 (ja) 2015-12-22 2021-10-06 シンジェンタ パーティシペーションズ アーゲー 有害生物防除活性ピラゾール誘導体
EP3290416A1 (de) 2016-08-31 2018-03-07 AXXAM S.p.A. Substituierte n-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- und n-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamid- derivate und ihre verwendung als p2x7 rezeptor antagonist
EP3290417A1 (de) 2016-08-31 2018-03-07 AXXAM S.p.A. 2-chloro-n-[2-(1,3-thiazol-5-yl)ethyl]-5-(5-fluoropyrimidin-2-yl)-benzamide und ihre verwendung als p2x7 rezeptor antagonisten
BR112019006675A2 (pt) 2016-10-17 2019-06-25 Shionogi & Co derivado heterocíclico nitrogenado bicíclico e composição farmacêutica contendo o mesmo
EP3398941A1 (de) 2017-05-03 2018-11-07 AXXAM S.p.A. Heterozyklische p2x7-antagonisten
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CA3168533A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
EP4015039A1 (de) 2020-12-18 2022-06-22 AXXAM S.p.A. Heterocyclische derivate als p2x7-rezeptor-antagonisten
WO2023031319A1 (en) 2021-09-03 2023-03-09 Axxam S.P.A. 2,4-dihydro-3h-1,2,4-triazol-3-one p2x7 antagonists

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR80558B (en) 1983-10-08 1985-02-06 Nippon Kayaku Kk Derivative of pyrazole and use thereof as a herbicide
US5128351A (en) 1990-05-04 1992-07-07 American Cyanamid Company Bis-aryl amide and urea antagonists of platelet activating factor
US5077409A (en) 1990-05-04 1991-12-31 American Cyanamid Company Method of preparing bis-aryl amide and urea antagonists of platelet activating factor
US5281571A (en) 1990-10-18 1994-01-25 Monsanto Company Herbicidal benzoxazinone- and benzothiazinone-substituted pyrazoles
HUT64676A (en) 1990-12-17 1994-02-28 Shell Int Research Fungicidal compositions containing isoquinoline derivatives as actvie agent and process for production of the active agents
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
US5686061A (en) 1994-04-11 1997-11-11 The Board Of Regents Of The University Of Texas System Particulate contrast media derived from non-ionic water soluble contrast agents for CT enhancement of hepatic tumors
HRP950330A2 (en) * 1994-07-05 1997-10-31 Ciba Geigy Ag New herbicides
US6147101A (en) 1995-06-02 2000-11-14 Kyorin Pharmaceutical Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and process for producing the same
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US6001862A (en) 1995-06-02 1999-12-14 Kyorin Pharameuticals Co., Ltd. N-benzyldioxothiazolidylbenzamide derivatives and processes for preparing the same
US5672715A (en) * 1995-06-07 1997-09-30 Monsanto Company Herbicidal substituted 3-aryl-pyrazoles
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5939418A (en) 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
ES2162676T3 (es) 1996-03-29 2002-01-01 Searle & Co Derivados de fenileno sustituidos en meta y su uso como antagonistas o inhibidores de integrina alfav,beta3.
US6187797B1 (en) 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
DE19701287A1 (de) 1997-01-16 1998-07-23 Wernicke & Co Gmbh Verfahren zum Erhöhen der Gebrauchsdauer von Schleifscheiben
WO1998042669A1 (en) 1997-03-25 1998-10-01 Astra Pharmaceuticals Ltd. Novel pyridine derivatives and pharmaceutical compositions containing them
AU7210398A (en) 1997-03-27 1998-10-22 Novartis Ag Intermediate products and method for the production of pyrimidine derivatives
DE19719621A1 (de) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
JPH11318492A (ja) 1998-03-09 1999-11-24 Aisin Seiki Co Ltd 蛍光発生性基質を含有する組成物
JP2001508811A (ja) * 1998-04-20 2001-07-03 藤沢薬品工業株式会社 ｃＧＭＰ−ホスホジエステラーゼ阻害剤としてのアントラニル酸誘導体
US6320078B1 (en) 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
FR2783519B1 (fr) 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
DE19851184A1 (de) 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
KR20010086112A (ko) 1998-12-16 2001-09-07 빌프리더 하이더 인테그린 길항제로서의 신규한 비페닐 및 비페닐 유사화합물
BR0009651A (pt) * 1999-04-09 2002-01-08 Astrazeneca Ab Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
AU5158100A (en) 1999-05-24 2000-12-12 Cor Therapeutics, Inc. Inhibitors of factor xa
SE9904505D0 (sv) 1999-12-09 1999-12-09 Astra Pharma Prod Novel compounds
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
SE9904738D0 (sv) 1999-12-22 1999-12-22 Astra Pharma Prod Novel compounds
DE10005284A1 (de) 2000-02-07 2001-08-09 Bayer Ag Verfahren zur Herstellung von 1-Amino-3-aryl-uracilen
GB0006721D0 (en) 2000-03-20 2000-05-10 Mitchell Thomas A Assessment methods and systems
JP4160295B2 (ja) * 2000-12-08 2008-10-01 武田薬品工業株式会社 ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途
DE60139639D1 (de) * 2000-12-08 2009-10-01 Takeda Pharmaceutical Substituierte thiazolderivate mit 3-pyridylgruppen, verfahren zu deren herstellung und deren verwendung
EP1392643B1 (de) * 2001-05-18 2005-09-14 Abbott Laboratories Trisubstituierte-n-((1s)-1,2,3,4-tetrahydro-1-naphthalenyl) benzamide welche p2x3 und p2x2/3 enthaltende rezeptoren inhibieren
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
EP1501514B1 (de) * 2002-05-03 2012-12-19 Exelixis, Inc. Proteinkinasemodulatoren und verfahren zur derer anwendung
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
EP1562911B1 (de) * 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
AU2003288640A1 (en) * 2002-12-31 2004-07-22 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
JP4731468B2 (ja) 2003-05-12 2011-07-27 ファイザー・プロダクツ・インク Ｐ２ｘ７受容体のベンズアミド阻害剤
TWM244656U (en) * 2003-08-27 2004-09-21 Hon Hai Prec Ind Co Ltd Hinge mechanism
AU2005258911A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H`1,2,4!triazin-2-YL!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
EP1763353A1 (de) 2004-06-29 2007-03-21 Warner-Lambert Company LLC KOMBINATIONSTHERAPIEN MIT BENZAMID-HEMMERN DES P2X<SB>7</SB> REZEPTORS
WO2006003513A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3h-`1,2,4!-triazin-2-yl!benzamide derivatives with p2x7 inhibiting activity by reaction of the derivative unsubstituted in 4-position of the triazine with an oxiran in the presence of a lewis acid

Also Published As

Publication number Publication date
EP1626962B1 (de) 2007-02-28
US20050009900A1 (en) 2005-01-13
US7186742B2 (en) 2007-03-06
WO2004099146A1 (en) 2004-11-18
US7553972B2 (en) 2009-06-30
EP1626962A1 (de) 2006-02-22
CA2525437C (en) 2009-04-28
US20070142329A1 (en) 2007-06-21
ES2396565T3 (es) 2013-02-22
CA2525437A1 (en) 2004-11-18
DE602004005033T2 (de) 2007-08-09
MXPA05012086A (es) 2006-02-22
JP2006525991A (ja) 2006-11-16
JP4731468B2 (ja) 2011-07-27
BRPI0410349A (pt) 2006-05-30
ATE355273T1 (de) 2006-03-15
ES2281801T3 (es) 2007-10-01

Similar Documents

Publication Publication Date Title
DE602004005033D1 (de) Benzamidinhibitoren des p2x7-rezeptors
MY141984A (en) Benzamide inhibitors of the p2x7 receptor
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
MXJL05000010A (es) Compuestos de fenil-aza-benzimidazol para modular la ige e inhibir la proliferacion celular.
ATE533766T1 (de) Chinolinderivate als ep4-antagonisten
NO20056161L (no) Formuleringer for behandling av artrittilstander
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
BR0317844A (pt) Inibidores de benzamida do receptor p2x7
NO20055741D0 (no) Nye kjemiske forbindelser
EA200801372A1 (ru) Способы получения замещенных пиримидинов
NO20075269L (no) Fremgangsmate for fremstilling av opioidmodulatorer
NO20073790L (no) Kjemiske forbindelser
EA200970738A1 (ru) Ингибиторы активности akt
NO20060230L (no) Nye aminobenzofenonforbindelser
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
NO20076413L (no) Multisykliske forbindelser og fremgangsmater for deres anvendelse
TW200628463A (en) Heteroaryl compounds
DK1853588T3 (da) Kemiske forbindelser
ATE556060T1 (de) Monocyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
TW200603798A (en) Disalt inhibitors of il-12 production
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
TW200700064A (en) Novel compounds
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition